Marquette Asset Management LLC Sells 9,923 Shares of Nuvation Bio Inc. (NYSE:NUVB)

Marquette Asset Management LLC trimmed its holdings in shares of Nuvation Bio Inc. (NYSE:NUVB) by 15.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,114 shares of the company’s stock after selling 9,923 shares during the period. Marquette Asset Management LLC’s holdings in Nuvation Bio were worth $129,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Octagon Capital Advisors LP purchased a new position in shares of Nuvation Bio in the 4th quarter worth about $1,510,000. Susquehanna Fundamental Investments LLC purchased a new position in Nuvation Bio during the first quarter valued at $79,000. Pinnacle Wealth Planning Services Inc. bought a new stake in Nuvation Bio during the 1st quarter valued at about $105,000. Vanguard Group Inc. boosted its stake in Nuvation Bio by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 7,534,148 shares of the company’s stock valued at $27,424,000 after purchasing an additional 219,533 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Nuvation Bio by 81.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,174,464 shares of the company’s stock worth $4,273,000 after buying an additional 528,660 shares in the last quarter. 61.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

NUVB has been the topic of a number of research reports. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Nuvation Bio in a report on Wednesday, September 11th. HC Wainwright dropped their price target on Nuvation Bio from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $5.00 target price on shares of Nuvation Bio in a report on Tuesday, August 6th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $6.40.

Nuvation Bio Stock Performance

Nuvation Bio stock opened at $2.23 on Wednesday. Nuvation Bio Inc. has a 1 year low of $0.95 and a 1 year high of $4.16. The company’s fifty day moving average price is $2.85 and its 200 day moving average price is $3.02. The stock has a market capitalization of $551.19 million, a P/E ratio of -7.19 and a beta of 1.36.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.09). The firm had revenue of $1.44 million during the quarter. Sell-side analysts predict that Nuvation Bio Inc. will post -0.4 EPS for the current year.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.